Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Illucix and PSMA Imaging for the Initial Staging of Prostate Cancer
October 17, 2024 | 3:30 p.m. ET
This non-promotional webinar was developed and sponsored by Telix and is intended for healthcare professionals only.
The presentation focuses on Gallium 68-PSMA-11 (Illuccix) PET/CT imaging for Initial Staging of Prostate Cancer, Biochemical Recurrence and for the selection of patients for whom Lu177-PSMA-617 is indicated.
Dr. Naveen Kella is board certified in urology, with a fellowship in Urologic Oncology and robotic surgery. He is known for his experience in treating prostate cancer and has performed over 2,500 robotic prostate cancer surgeries. Dr. Kella is also an Adjunct Assistant Professor for the UT Health Science Center.
The presentation will include case studies illustrating the clinical utility of Illuccix for urology patients and provide an understanding of the mode of action for Illuccix and the radiographic PET/CT findings in prostate cancer.
Naveen Kella, MD
UCLA Health – Assistant Professor of Urology and Director of Research, Division of Female Pelvic Medicine and Reconstructive Surgery